Hoffmann-La Roche
Glofitamab(Hoffmann-La Roche)은 Chronic Lymphocytic Leukemia 표적 항체로, Diffuse Large B Cell Lymphoma (DLBCL); High Grade B Cell Lymphoma 영역에서 개발·상용화 중입니다. 작용기전: and pharmacokinetics of glofitamab. Phase 3 후기 임상 단계입니다. ClinicalTrials.gov 기준 66건의 관련 임상이 등록되어 있습니다. PK: t½ 7.6 h. 차별점: novel aspects of time toxicity, demonstrate clinically meaningful differences in time burden associated with BsAbs and emphas.
Chronic Lymphocytic Leukemia
Diffuse Large B Cell Lymphoma (DLBCL); High Grade B Cell Lymphoma
Recruiting
bispecific antibody approved for treatment of relapsed/refractory diff
vedotin plus bendamustine and rituximab (Pola-B
humanized lymphoma models, addressing heterogeneity of tumor antigen expression, immune evasion, and T-cell e
novel aspects of time toxicity, demonstrate clinically meaningful differences in time burden associated with BsAbs and emphas
and pharmacokinetics of glofitamab
Cytokine release syndrome occurred in all glofitamab-treated patients (grade 1/2/3: n = 3/n =&#
biomarker-guided sequencing, optimized toxicity/infection mitigation, and combination strategies that improve
resistance to glofitamab, a T-cell engager for treatment of large B-cell lymphoma
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Hoffmann-La Roche
Glofitamab(Hoffmann-La Roche)은 Chronic Lymphocytic Leukemia 표적 항체로, Diffuse Large B Cell Lymphoma (DLBCL); High Grade B Cell Lymphoma 영역에서 개발·상용화 중입니다. 작용기전: and pharmacokinetics of glofitamab. Phase 3 후기 임상 단계입니다. ClinicalTrials.gov 기준 66건의 관련 임상이 등록되어 있습니다. PK: t½ 7.6 h. 차별점: novel aspects of time toxicity, demonstrate clinically meaningful differences in time burden associated with BsAbs and emphas.
Chronic Lymphocytic Leukemia
Diffuse Large B Cell Lymphoma (DLBCL); High Grade B Cell Lymphoma
Recruiting
bispecific antibody approved for treatment of relapsed/refractory diff
vedotin plus bendamustine and rituximab (Pola-B
humanized lymphoma models, addressing heterogeneity of tumor antigen expression, immune evasion, and T-cell e
novel aspects of time toxicity, demonstrate clinically meaningful differences in time burden associated with BsAbs and emphas
and pharmacokinetics of glofitamab
Cytokine release syndrome occurred in all glofitamab-treated patients (grade 1/2/3: n = 3/n =&#
biomarker-guided sequencing, optimized toxicity/infection mitigation, and combination strategies that improve
resistance to glofitamab, a T-cell engager for treatment of large B-cell lymphoma
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.